Saluda Medical Releases CAP24™ Across the US

Saluda Medical announced the full US commercial release of its CAP24™ Surgical Paddle Lead, according to Newswise. The company said the release follows FDA approval earlier this year.

The announcement marks a commercial-access milestone for Saluda Medical’s closed-loop neuromodulation platform in the US. Newswise identified Saluda as a commercial-stage medical device company developing treatments for chronic neurological conditions.

CAP24™ reaches full US commercial release

According to the Newswise announcement, CAP24™ is a Surgical Paddle Lead that has entered full US commercial release. Saluda Medical said FDA approval earlier this year preceded the release.

Newswise reported that Saluda describes CAP24™ as the first and only FDA-approved closed-loop surgical paddle lead. The company presented the release as an expansion of access to the product in the US market.

The reported milestone combines regulatory status and commercial availability: FDA approval earlier this year and a subsequent full US commercial release. Saluda Medical’s announcement specifically concerns CAP24™ and its Surgical Paddle Lead designation.

Closed-loop neuromodulation focus

Newswise described Saluda Medical as focused on developing treatments for chronic neurological conditions. The company’s stated work centers on a novel closed-loop neuromodulation platform.

For medical device sales professionals following market-access developments, the announcement provides a current product-release update in neuromodulation. The relevant reported details are the full US commercial release, the earlier FDA approval, and Saluda Medical’s description of CAP24™ as a closed-loop surgical paddle lead.

What the announcement establishes

• CAP24™ Surgical Paddle Lead is in full US commercial release, according to Saluda Medical.
• The release follows FDA approval earlier this year.
• Saluda Medical describes CAP24™ as the first and only FDA-approved closed-loop surgical paddle lead.
• The company focuses on treatments for chronic neurological conditions using a closed-loop neuromodulation platform.

Newswise published the company’s announcement as a US commercial-release development for CAP24™. The release places the product within Saluda Medical’s broader stated focus on closed-loop neuromodulation and chronic neurological conditions.